1. Home
  2. SNTG vs NEUP Comparison

SNTG vs NEUP Comparison

Compare SNTG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNTG
  • NEUP
  • Stock Information
  • Founded
  • SNTG 2009
  • NEUP 1996
  • Country
  • SNTG China
  • NEUP United States
  • Employees
  • SNTG N/A
  • NEUP N/A
  • Industry
  • SNTG Finance: Consumer Services
  • NEUP
  • Sector
  • SNTG Finance
  • NEUP
  • Exchange
  • SNTG Nasdaq
  • NEUP Nasdaq
  • Market Cap
  • SNTG 5.9M
  • NEUP 17.4B
  • IPO Year
  • SNTG 2021
  • NEUP N/A
  • Fundamental
  • Price
  • SNTG $1.95
  • NEUP $4.49
  • Analyst Decision
  • SNTG
  • NEUP Strong Buy
  • Analyst Count
  • SNTG 0
  • NEUP 1
  • Target Price
  • SNTG N/A
  • NEUP $21.00
  • AVG Volume (30 Days)
  • SNTG 443.3K
  • NEUP 1.4M
  • Earning Date
  • SNTG 12-17-2024
  • NEUP 02-13-2025
  • Dividend Yield
  • SNTG N/A
  • NEUP N/A
  • EPS Growth
  • SNTG N/A
  • NEUP N/A
  • EPS
  • SNTG N/A
  • NEUP N/A
  • Revenue
  • SNTG $146,472.00
  • NEUP N/A
  • Revenue This Year
  • SNTG N/A
  • NEUP N/A
  • Revenue Next Year
  • SNTG N/A
  • NEUP N/A
  • P/E Ratio
  • SNTG N/A
  • NEUP N/A
  • Revenue Growth
  • SNTG N/A
  • NEUP N/A
  • 52 Week Low
  • SNTG $1.65
  • NEUP $2.12
  • 52 Week High
  • SNTG $3.97
  • NEUP $16.08
  • Technical
  • Relative Strength Index (RSI)
  • SNTG 51.22
  • NEUP N/A
  • Support Level
  • SNTG $1.73
  • NEUP N/A
  • Resistance Level
  • SNTG $1.92
  • NEUP N/A
  • Average True Range (ATR)
  • SNTG 0.29
  • NEUP 0.00
  • MACD
  • SNTG 0.01
  • NEUP 0.00
  • Stochastic Oscillator
  • SNTG 15.71
  • NEUP 0.00

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

About NEUP Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Share on Social Networks: